STAG2 and Ewing sarcoma: The development of in vivo models and analysis of the immune environment in patients with and without STAG2 mutations will be important future directions for exploring the contribution of immune evasion to aggressive Ewing sarcoma and its implications for immunotherapy (Visser et al, 2023).